search
Back to results

BPL-003 Efficacy and Safety in Treatment Resistant Depression

Primary Purpose

Treatment Resistant Depression

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BPL-003
Sponsored by
Beckley Psytech Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Treatment Resistant Depression

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: At least moderate major depressive disorder. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments based on the MGH ATRQ assessment. Hamilton Depression Rating Scale score ≥19 at Screening and Baseline. CGI-S ≥4 at Screening and Baseline. If currently taking antidepressant medications, willing and able to discontinue current antidepressants. Exclusion Criteria: Current or past history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder. Current personality disorders. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, or schizoaffective disorder. Current alcohol or substance use disorder (other than caffeine or nicotine). A participant who at any time has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation. Suicidal ideation or behavior within the 12 months prior to the start of Screening or on Day 1 prior to dosing. Suicide attempt and/or self-injurious behavior within the last 12 months prior to Screening. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure. History or current uncontrolled hypertension. Seizure disorder or any seizure in the 2 years prior to Screening. Has clinically significant results on ECG during the Screening. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing that in the investigator's opinion may interfere with the administration of the study medication. Female participants who are pregnant, lactating, or of childbearing potential and not willing to use adequate forms of contraception during the study. Male participants who are sexually active and not willing to use adequate forms of contraception during the study.

Sites / Locations

  • New York State Psychiatric Institute
  • Royal Prince Alfred HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Low dose

Medium dose

High dose

Arm Description

Active placebo comparator

Outcomes

Primary Outcome Measures

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
High compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.

Secondary Outcome Measures

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
High compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Medium compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.
Safety of BPL-003 given with psychological support as assessed by number and percentage of participants with adverse events
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant abnormal laboratory tests
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant abnormal vital sign measurements
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant ECG parameters compared
Safety of BPL-003 given with psychological support as assessed by incidence of suicidal ideation or behavior
Plasma levels of 5-MeO-DMT and its metabolites

Full Information

First Posted
May 12, 2023
Last Updated
September 20, 2023
Sponsor
Beckley Psytech Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05870540
Brief Title
BPL-003 Efficacy and Safety in Treatment Resistant Depression
Official Title
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients With Treatment Resistant Depression
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2023 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beckley Psytech Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).
Detailed Description
Approximately 225 eligible participants will be receive a single dose of either low, medium, or high doses BPL-003, given intranasally, with 8 weeks of follow-up assessments. Psychological support will be given before, during and after dosing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment Resistant Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Quadruple masking: participant, Investigator, therapist, outcomes assessor and Sponsor
Allocation
Randomized
Enrollment
225 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low dose
Arm Type
Experimental
Arm Description
Active placebo comparator
Arm Title
Medium dose
Arm Type
Experimental
Arm Title
High dose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BPL-003
Intervention Description
A single dose administered intranasally
Primary Outcome Measure Information:
Title
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Description
High compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Description
High compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.
Time Frame
1 week
Title
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Medium compared to low dose of BPL-003. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0-6.
Time Frame
4 weeks and 1 week
Title
Safety of BPL-003 given with psychological support as assessed by number and percentage of participants with adverse events
Time Frame
8 weeks
Title
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant abnormal laboratory tests
Time Frame
8 weeks
Title
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant abnormal vital sign measurements
Time Frame
8 weeks
Title
Safety of BPL-003 given with psychological support as assessed by percentage of participants with clinically significant ECG parameters compared
Time Frame
8 weeks
Title
Safety of BPL-003 given with psychological support as assessed by incidence of suicidal ideation or behavior
Time Frame
8 weeks
Title
Plasma levels of 5-MeO-DMT and its metabolites
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least moderate major depressive disorder. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments based on the MGH ATRQ assessment. Hamilton Depression Rating Scale score ≥19 at Screening and Baseline. CGI-S ≥4 at Screening and Baseline. If currently taking antidepressant medications, willing and able to discontinue current antidepressants. Exclusion Criteria: Current or past history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder. Current personality disorders. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, or schizoaffective disorder. Current alcohol or substance use disorder (other than caffeine or nicotine). A participant who at any time has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation. Suicidal ideation or behavior within the 12 months prior to the start of Screening or on Day 1 prior to dosing. Suicide attempt and/or self-injurious behavior within the last 12 months prior to Screening. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure. History or current uncontrolled hypertension. Seizure disorder or any seizure in the 2 years prior to Screening. Has clinically significant results on ECG during the Screening. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing that in the investigator's opinion may interfere with the administration of the study medication. Female participants who are pregnant, lactating, or of childbearing potential and not willing to use adequate forms of contraception during the study. Male participants who are sexually active and not willing to use adequate forms of contraception during the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Beckley Psytech Ltd
Phone
+44 (0)1865 987633
Email
Medinfo@beckleypsytech.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer, MD, PhD
Organizational Affiliation
Beckley Psytech Ltd
Official's Role
Study Director
Facility Information:
Facility Name
New York State Psychiatric Institute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Royal Prince Alfred Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Due to the GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion

Learn more about this trial

BPL-003 Efficacy and Safety in Treatment Resistant Depression

We'll reach out to this number within 24 hrs